Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid

JAMA Dermatol. 2017 Jun 1;153(6):603-605. doi: 10.1001/jamadermatol.2017.0091.

Authors

Laura Sowerby¹, Anna K Dewan¹, Scott Granter², Leena Gandhi³, Nicole R LeBoeuf¹

Affiliations

¹ The Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
² Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
³ The Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

PMID: 28355425
DOI: 10.1001/jamadermatol.2017.0091

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Aged, 80 and over
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use
Biopsy
Follow-Up Studies
Humans
Immunologic Factors / therapeutic use
Lung Neoplasms / drug therapy
Male
Nivolumab / adverse effects*
Nivolumab / therapeutic use
Pemphigoid, Bullous / chemically induced
Pemphigoid, Bullous / diagnosis
Pemphigoid, Bullous / drug therapy*
Rituximab / therapeutic use*
Skin / drug effects
Skin / pathology*

Substances

Antineoplastic Agents, Immunological
Immunologic Factors
Nivolumab
Rituximab